Ofranergene obadenovec

VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111

Retrieved on: 
Tuesday, April 21, 2020
Health, Medicine, RTT, Oncology, Gynaecological cancer, Gynaecology, Ovarian cancer, Therapy, Cancer, Ofranergene obadenovec, Targeted therapy

The funds will support the continued development of VBL's lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent.

Key Points: 
  • The funds will support the continued development of VBL's lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent.
  • VB-111 is currently being evaluated in a Phase 3 potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer.
  • According to the interim data, the response rate in the treatment arm was 58% or higher.
  • VB-111 is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.

Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier

Retrieved on: 
Thursday, April 2, 2020
RTT, Gynaecology, Medicine, Clinical medicine, Oncology, Gynaecological cancer, Ofranergene obadenovec, Ovarian cancer, Cancer, Ovary

VBL and NanoCarrier Co. Ltd. signed an exclusive license agreement in 2017 for the development, commercialization, and supply of VB-111 in Japan.

Key Points: 
  • VBL and NanoCarrier Co. Ltd. signed an exclusive license agreement in 2017 for the development, commercialization, and supply of VB-111 in Japan.
  • There are more than 10,000 women diagnosed with ovarian cancer in Japan with more than 5,000 associated deaths annually.
  • The Data Safety Monitoring Committee (DSMC) overseeing OVAL recently conducted a preplanned interim analysis and recommended that the study continue.
  • We are very pleased that NanoCarrier has chosen to develop VB-111 in ovarian cancer in Japan, said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics.

VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19

Retrieved on: 
Monday, March 2, 2020
Health, Medicine, RTT, Oncology, Ofranergene obadenovec, Ovarian cancer, Cancer, Therapy, Targeted therapy

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.
  • It is conveniently administered as an IV infusion once every two months.
  • Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.

VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer

Retrieved on: 
Thursday, February 20, 2020
Clinical medicine, Medicine, Antineoplastic drugs, Immune system, Bristol-Myers Squibb, Monoclonal antibodies, Cancer treatments, Nivolumab, Ofranergene obadenovec, Programmed cell death protein 1, Checkpoint inhibitor, Cancer

TEL AVIV, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the launch of a phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo), an immune checkpoint inhibitor, in the treatment of metastatic colorectal cancer.

Key Points: 
  • TEL AVIV, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the launch of a phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo), an immune checkpoint inhibitor, in the treatment of metastatic colorectal cancer.
  • This new study will investigate if priming with VB-111 can drive immune cells into the tumor and turn the colorectal tumor from immunologically cold to hot.
  • The goal of this open-label, single-arm phase 2 study is to evaluate VB-111 in combination with an anti-PD-1 inhibitor, nivolumab, in patients with metastatic colorectal cancer.
  • Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.

VBL Therapeutics to Present at the BIO CEO & Investor Conference

Retrieved on: 
Monday, February 3, 2020
Cancer, Clinical medicine, Medicine, Oncology, Ofranergene obadenovec, Ovarian cancer, Biogen

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • It is conveniently administered as an IV infusion once every two months.
  • Ofranergene obadenovec is currently being studied in a Phase 3 potential registration trial for platinum-resistant ovarian cancer.
  • VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Thursday, November 21, 2019
Cancer treatments, Cancer, Clinical medicine, RTT, Oncology, Gynaecological cancer, Gynaecology, Ovarian cancer, Ofranergene obadenovec, Mapatumumab, Genelux Corporation

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • It is conveniently administered as an IV infusion once every two months.
  • It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an all comers Phase 1 trial as well as in three tumor-specific Phase 2 studies.
  • Ofranergene obadenovec is currently being studied in a Phase 3 potential registration trial for platinum-resistant ovarian cancer.

VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

Retrieved on: 
Wednesday, November 6, 2019
Cancer, Clinical medicine, Medicine, Ofranergene obadenovec, Oncology

The IND is for a Phase 2 randomized, controlled, clinical trial of VB-111 in rGBM patients undergoing a second surgery.

Key Points: 
  • The IND is for a Phase 2 randomized, controlled, clinical trial of VB-111 in rGBM patients undergoing a second surgery.
  • The IND was submitted by Patrick Wen, M.D., Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on behalf of a group of top neuro-oncology US medical centers.
  • "MRI analysis conducted at UCLA of the VB-111 Phase 2 and GLOBE Phase 3 studies demonstrated objective responses to VB-111 monotherapy.
  • Ofranergene obadenovec is currently being studied in a Phase 3 potential registration trial for platinum-resistant ovarian cancer.

VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

Retrieved on: 
Thursday, October 31, 2019
Health, Medicine, Cancer, RTT, Gynaecological cancer, Gynaecology, Ovarian cancer, Antineoplastic drugs, Ofranergene obadenovec, Therapy, Oncology, Targeted therapy

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • The Companys lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.
  • It is conveniently administered as an IV infusion once every two months.
  • Ofranergene obadenovec is currently being studied in a potential registration trial for platinum-resistant ovarian cancer.

VBL Therapeutics Announces Second Quarter 2019 Financial Results

Retrieved on: 
Tuesday, August 13, 2019
Ofranergene obadenovec, NASDAQ, Finance, Economy of the United States

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update.

Key Points: 
  • TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update.
  • Our OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer continues as planned, said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.
  • Second Quarter ended June 30, 2019 Financial Results:
    Cash Position: At June 30, 2019, the Company had cash, cash equivalents and short-term bank deposits totaling $45.1 million and working capital of $39.1 million.
  • Revenues: Revenues related to VBLs collaborations were $0.1 million in the second quarter of 2019.

VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13

Retrieved on: 
Monday, August 5, 2019
Health, Medicine, Cancer, RTT, Gynaecological cancer, Gynaecology, Ovarian cancer, Antineoplastic drugs, Ofranergene obadenovec, Therapy, Oncology, Targeted therapy, Health, Medicine, Cancer, RTT, Gynaecological cancer, Gynaecology, Ovarian cancer, Antineoplastic drugs, Ofranergene obadenovec, Therapy, Oncology, Targeted therapy

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • The Companys lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.
  • It is conveniently administered as an IV infusion once every two months.
  • Ofranergene obadenovec is currently being studied in a potential registration trial for platinum-resistant ovarian cancer.